Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E. Gray, Thomas J. Dilling, Joel W. Neal, Heather A. Wakelee, Yufei Liu, Steven H. Lin, Tariq Abuali, Arya Amini, Yunan Nie, Tejas Patil, Anastasiya Lobachov, Jair Bar, Bailey FitzgeraldYu Fujiwara, Thomas U. Marron, Rohit Thummalapalli, Helena Yu, Dwight H. Owen, John Sharp, Saira Farid, Pedro Rocha, Edurne Arriola, Angelica D'Aiello, Haiying Cheng, Ryan Whitaker, Kaushal Parikh, Yash Ashara, Luxi Chen, Kamya Sankar, Jeremy P. Harris, Misako Nagasaka, Adanma Ayanambakkam, Ana I. Velazquez, Meera Ragavan, Jessica J. Lin, Zofia Piotrowska, Molly Wilgucki, Joshua Reuss, Heike Luders, Christian Grohe, Javier Baena Espinar, Ella Feiner, Salman R. Punekar, Shruti Gupta, Ticiana Leal, David J. Kwiatkowski, Raymond H. Mak, Elio Adib, Abdul Rafeh Naqash, Sarah B. Goldberg

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study'. Together they form a unique fingerprint.

Medicine & Life Sciences